Director/PDMR Shareholding

Synairgen plc
08 November 2006

Director Shareholdings

Synairgen plc ('Synairgen' or the 'Company')

The Company was informed on 7 November 2006 that Dr David Bruce Campbell,
Non-executive Director of Synairgen and Executive Director and Chief Scientific
Officer of IP Group plc, acquired a beneficial interest in 216,923 ordinary
shares of 1p each in the Company ('Ordinary Shares') on 7 November 2006. This
beneficial interest results from the transfer of Ordinary Shares from IP Group
plc to Dr David Bruce Campbell for nil consideration as part of the IP Group plc
bonus scheme.  As a consequence his holding in the Company equates to 216,923
Ordinary Shares, which represents approximately 1.00 per cent. of the issued
ordinary share capital of the Company.


                      This information is provided by RNS
            The company news service from the London Stock Exchange